- Home
- MIRM vs MTN Comparison
MIRM vs MTN Comparison
Compare MIRM & MTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRM
- MTN
- Stock Information
- Founded
- MIRM 2018
- MTN 1997
- Country
- MIRM United States
- MTN United States
- Employees
- MIRM N/A
- MTN N/A
- Industry
- MIRM Biotechnology: Pharmaceutical Preparations
- MTN Services-Misc. Amusement & Recreation
- Sector
- MIRM Health Care
- MTN Consumer Discretionary
- Exchange
- MIRM Nasdaq
- MTN Nasdaq
- Market Cap
- MIRM 1.9B
- MTN N/A
- IPO Year
- MIRM 2019
- MTN 1997
- Fundamental
- Price
- MIRM $39.10
- MTN $138.43
- Analyst Decision
- MIRM Strong Buy
- MTN Hold
- Analyst Count
- MIRM 11
- MTN 9
- Target Price
- MIRM $58.55
- MTN $193.33
- AVG Volume (30 Days)
- MIRM 476.2K
- MTN 695.0K
- Earning Date
- MIRM 05-07-2025
- MTN 06-05-2025
- Dividend Yield
- MIRM N/A
- MTN 6.42%
- EPS Growth
- MIRM N/A
- MTN 10.73
- EPS
- MIRM N/A
- MTN 6.89
- Revenue
- MIRM $336,888,000.00
- MTN $2,946,168,000.00
- Revenue This Year
- MIRM $29.51
- MTN $4.74
- Revenue Next Year
- MIRM $20.27
- MTN $4.20
- P/E Ratio
- MIRM N/A
- MTN $20.09
- Revenue Growth
- MIRM 80.76
- MTN 3.57
- 52 Week Low
- MIRM $23.14
- MTN $129.85
- 52 Week High
- MIRM $54.23
- MTN $219.84
- Technical
- Relative Strength Index (RSI)
- MIRM 34.64
- MTN 37.58
- Support Level
- MIRM $37.83
- MTN $129.85
- Resistance Level
- MIRM $40.32
- MTN $145.23
- Average True Range (ATR)
- MIRM 2.47
- MTN 6.72
- MACD
- MIRM -0.33
- MTN -0.98
- Stochastic Oscillator
- MIRM 25.14
- MTN 25.73
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.